Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

P/FCFE
Price to FCFE

-26.8
Current
-5.5
Median
23.6
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-26.8
=
Market Cap
189.1m AUD
/
FCFE
-7m AUD
All Countries
All Countries
Close
Market Cap P/FCFE
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD -26.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -40 845 137.7
US
Eli Lilly and Co
NYSE:LLY
744.2B USD 92.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 2 143.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 34.8
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 12.9
US
Merck & Co Inc
NYSE:MRK
258.4B USD 15.7
CH
Roche Holding AG
SIX:ROG
200.6B CHF 20.1
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 22.6
CH
Novartis AG
SIX:NOVN
180.7B CHF 11.7
US
Pfizer Inc
NYSE:PFE
146.9B USD 25.5

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Summary
ALA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALA stock valuation using valuation multiples.
Wall Street Estimates
ALA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 202,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.